Memristor-CMOS Hybrid Neuron Circuit with Nonideal-Effect Correction Related to Parasitic Resistance for Binary-Memristor-Crossbar Neural Networks

Voltages and currents in a memristor crossbar can be significantly affected due to nonideal effects such as parasitic source, line, and neuron resistance. These nonideal effects related to the parasitic resistance can cause the degradation of the neural network’s performance realized with the nonideal memristor crossbar. To avoid performance degradation due to the parasitic-resistance-related nonideal effects, adaptive training methods were proposed previously. However, the complicated training algorithm could add a heavy computational burden to the neural network hardware. Especially, the hardware and algorithmic burden can be more serious for edge intelligence applications such as Internet of Things (IoT) sensors. In this paper, a memristor-CMOS hybrid neuron circuit is proposed for compensating the parasitic-resistance-related nonideal effects during not the training phase but the inference one, where the complicated adaptive training is not needed. Moreover, unlike the previous linear correction method performed by the external hardware, the proposed correction circuit can be included in the memristor crossbar to minimize the power and hardware overheads for compensating the nonideal effects. The proposed correction circuit has been verified to be able to restore the degradation of source and output voltages in the nonideal crossbar. For the source voltage, the average percentage error of the uncompensated crossbar is as large as 36.7%. If the correction circuit is used, the percentage error in the source voltage can be reduced from 36.7% to 7.5%. For the output voltage, the average percentage error of the uncompensated crossbar is as large as 65.2%. The correction circuit can improve the percentage error in the output voltage from 65.2% to 8.6%. Almost the percentage error can be reduced to ~1/7 if the correction circuit is used. The nonideal memristor crossbar with the correction circuit has been tested for MNIST and CIFAR-10 datasets in this paper. For MNIST, the uncompensated and compensated crossbars indicate the recognition rate of 90.4% and 95.1%, respectively, compared to 95.5% of the ideal crossbar. For CIFAR-10, the nonideal crossbars without and with the nonideal-effect correction show the rate of 85.3% and 88.1%, respectively, compared to the ideal crossbar achieving the rate as large as 88.9%.

Nanotechnology based solutions for anti-leishmanial impediments: a detailed insight

As a neglected tropical disease, Leishmaniasis is significantly instigating morbidity and mortality across the globe. Its clinical spectrum varies from ulcerative cutaneous lesions to systemic immersion causing hyperthermic hepato-splenomegaly. Curbing leishmanial parasite is toughly attributable to the myriad obstacles in existing chemotherapy and immunization. Since the 1990s, extensive research has been conducted for ameliorating disease prognosis, by resolving certain obstacles of conventional therapeutics viz. poor efficacy, systemic toxicity, inadequate drug accumulation inside the macrophage, scarce antigenic presentation to body’s immune cells, protracted length and cost of the treatment. Mentioned hurdles can be restricted by designing nano-drug delivery system (nano-DDS) of extant anti-leishmanials, phyto-nano-DDS, surface modified—mannosylated and thiolated nano-DDS. Likewise, antigen delivery with co-transportation of suitable adjuvants would be achievable through nano-vaccines. In the past decade, researchers have engineered nano-DDS to improve the safety profile of existing drugs by restricting their release parameters. Polymerically-derived nano-DDS were found as a suitable option for oral delivery as well as SLNs due to pharmacokinetic re-modeling of drugs. Mannosylated nano-DDS have upgraded macrophage internalizing of nanosystem and the entrapped drug, provided with minimal toxicity. Cutaneous Leishmaniasis (CL) was tackling by the utilization of nano-DDS designed for topical delivery including niosomes, liposomes, and transfersomes. Transfersomes, however, appears to be superior for this purpose. The nanotechnology-based solution to prevent parasitic resistance is the use of Thiolated drug-loaded and multiple drugs loaded nano-DDS. These surfaces amended nano-DDS possess augmented IC50 values in comparison to conventional drugs and un-modified nano-DDS. Phyto-nano-DDS, another obscure horizon, have also been evaluated for their anti-leishmanial response, however, more intense assessment is a prerequisite. Impoverished Cytotoxic T-cells response followed by Leishmanial antigen proteins delivery have also been vanquished using nano-adjuvants. The eminence of nano-DDS for curtailment of anti-leishmanial chemotherapy and immunization associated challenges are extensively summed up in this review. This expedited approach is ameliorating the Leishmaniasis management successfully. Alongside, total to partial eradication of this disease can be sought along with associated co-morbidities.

Combination of immunostimulants with moxidectin in the treatment of animals experimentally infected with Haemonchus contortus

Considering the importance of Haemonchus contortus infection in herds along with parasitic resistance, the goal of this study was to evaluate the influence of the administration of adjuvants alone or in combination with anthelmintics for the treatment of H. contortus, in experimentally infected sheep. Thirty sheep of the Texel breed of both genders, raised in a herd located in the subtropical region of Brazil, were used in this experiment. Experimental infection with H. contortus was performed in sheep, and the infected sheep were then separated into groups for the administration of antiparasitic and immunostimulant drugs. The results obtained from the excretion of eggs per gram of feces and the count of parasites during necropsy affirm that the use of adjuvants in combination with anthelmintics is associated with higher efficacy of treatment, lower rate of reinfection, and retardation in the development of anthelmintic drug resistance by H. contortus. Based on these results, we can conclude that the combination of anthelmintics and immunostimulants may favor potential anthelmintic treatments for H. contortus.